The NSDHL (NAD(P)H steroid dehydrogenase-like protein) antibody is a tool used to detect the NSDHL enzyme, encoded by the NSDHL gene, which plays a critical role in cholesterol biosynthesis. NSDHL functions as a C-4 sterol demethylase in the post-squalene cholesterol synthesis pathway, catalyzing sequential removal of methyl groups during lanosterol conversion to cholesterol. Located in the endoplasmic reticulum, NSDHL also interacts with lipid rafts, influencing cell signaling and membrane dynamics. Research involving NSDHL antibodies focuses on elucidating its role in cholesterol homeostasis, developmental biology, and disease. Mutations in NSDHL are linked to CHILD syndrome, an X-linked dominant disorder characterized by congenital hemidysplasia, ichthyosiform skin lesions, and limb defects. Additionally, NSDHL dysregulation has been implicated in cancers, as cholesterol metabolism supports tumor growth and metastasis. The antibody enables detection of NSDHL expression in tissues or cultured cells via techniques like Western blot, immunohistochemistry, and immunofluorescence. Its applications span studying metabolic disorders, genetic diseases, and cancer biology, with potential relevance to therapeutic strategies targeting cholesterol pathways. Researchers also explore NSDHL's interactions with other enzymes in the sterol biosynthesis complex to better understand feedback mechanisms and regulatory networks.